1. At a Glance – Small Cap With Big Lactose Energy
Market cap ₹122 crore. Current price ₹97. Stock P/E 25.3. Price to Book 1.96. ROCE 12.9%. ROE 9.69%. Promoter holding 53.6% with 26.1% pledged. Debt ₹54.2 crore.
Welcome to the world of Lactose (India) Ltd, where milk sugar meets pharma chemistry and your portfolio meets volatility.
Q3 FY26 (Dec 2025) numbers:
Sales at ₹36.77 crore (up 28% YoY).
PAT at ₹0.53 crore (up 141% YoY).
EPS ₹0.42 for the quarter.
But wait.
TTM profit is ₹4.83 crore and profit growth is actually negative 30% over TTM. Six-month return? -16.4%. Three-month return? -23.2%. One-year return? -20.7%.
So what is this stock?
A turnaround story?
A debt-loaded excipient supplier?
Or just a lactose-powered roller coaster?
Let’s open the balance sheet microscope and find out.
2. Introduction – Milk Sugar With a Pharma Degree
Incorporated in 1991, Lactose (India) Ltd manufactures pharmaceutical products and does job work. Sounds boring? Wait.
They produce lactose powder, lactulose (API), and tablets. Lactose here isn’t the thing that makes you bloated after ice cream — it’s an excipient. A binder. The unsung hero that holds your medicine together.
The company is associated with Kerry Group and works across food, dairy, pharma, bulk drugs, chemicals, intermediates — basically, if it can be powdered, processed, or chemically complicated, they’ll touch it.
Clients include heavyweights like Abbott, Biocon, Glenmark, Intas, Ipca, Lupin, P&G, Pfizer, Sun Pharma, Sanofi, Wockhardt, Zydus.
Sounds impressive, right?
But here’s the twist.
Despite big-name clients, ROE is under 10%. Promoters have pledged 26.1%. Debt-to-equity sits at 0.87. Interest coverage only 2.25.
So question:
If you’re supplying to pharma giants, why are returns still mediocre?
Let’s go deeper.
3. Business Model – WTF Do They Even Do?
Imagine this.
You’re a pharma company. You’ve made the magical drug molecule. But it’s tiny. You can’t sell a molecule dust particle.
You need bulk. You need binding. You need stability.
Enter Lactose (India).
They
